Outcomes of Functional Substrate Mapping of Ventricular Tachycardia
Sponsored by Mid and South Essex NHS Foundation Trust
About this trial
Last updated a year ago
Study ID
315453
Status
Recruiting
Type
Observational [Patient Registry]
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 6 months ago
What is this trial about?
The goal of this registry database is to demonstrate the safety and effectiveness of
functional ventricular tachycardia (VT) ablation using SENSE protocol in patients with
ischaemic VT. Mortality and the need for ICD therapies at 12 months post-ablation will be
compared with propensity-matched controls undergoing substrate-based ablation alone.
What are the participation requirements?
Inclusion Criteria
One of the following VT events (within the last 6 months) + Ejection Fraction <40%: A: ≥3 episodes of VT treated with anti-tachycardia pacing (ATP), at least one of which is symptomatic. B: ≥1 appropriate ICD shock. C: ≥3 VT episodes within 24 hr. D: Sustained VT below the detection rate of the ICD.
Exclusion Criteria
- Contraindication to VT ablation - Renal failure (CrCl < 15 mL/min) - NYHA IV or CCS IV angina - STEMI within 1 month - CABG within 3 months - PCI within 1 month - Pregnant - Life expectancy < 1 year
Locations
Location
Status
Recruiting